CAR-T CELL THERAPY BREAKTHROUGH IN SOLID TUMOURS

CAR-T CELL THERAPY BREAKTHROUGH IN SOLID TUMOURS

Why in the News?

• Scientists have developed a highly sensitive receptor (HIT receptor) that enables CAR-T cells to detect low-level tumour proteins.
• The breakthrough could make CAR-T therapy effective against solid cancers like kidney and ovarian cancer, overcoming a long-standing limitation.

Key scientific advancement

• Concept innovation: Uses an advanced form of CAR-T cell therapy to enhance tumour detection.
• New receptor design: HIT (HLA-independent T-cell) receptor links detection directly to natural immune activation pathways.
• Target protein: Focus on CD70 protein, present in many cancers but often at very low levels.
• Pseudo-heterogeneity: Tumour cells previously thought “invisible” actually contain trace proteins undetectable by conventional CAR-T cells.
• Improved sensitivity: Enables immune cells to detect faint antigen signals, leading to better tumour elimination.

Significance and challenges

• Expanding cancer treatment: May allow CAR-T therapy to treat solid tumours, not just blood cancers like leukaemia.
• Better tumour eradication: Eliminates residual cancer cells, reducing chances of relapse.
• Scientific impact: Advances understanding of quantum mechanics-like cellular behaviour in signalling and detection at microscopic levels (indirect relevance through molecular interactions).
• Safety concerns: Risk of attacking normal cells with low protein expression (“Goldilocks challenge”).
• Future pathway: Requires clinical trials and safety switches before real-world medical use.